Good day, ladies and gentlemen and welcome to the Fourth Quarter Nu Skin Enterprises Earnings Conference Call. My name is Philip and I'll be your operator for today. At this time, all participants are now in a listen-only mode. (Operator Instructions). As a reminder, this conference is being recorded for replay purposes. I would now like to turn the conference over to your host for today Mr. Scott Pond, Director of Investor Relations. Please proceed, sir.

Thanks, Philip. Good morning everyone. We appreciate you joining us. Today on the call with me are Truman Hunt, President and Chief Executive Officer; Ritch Wood, Chief Financial Officer; Dr. Joe Chang, Chief Scientific Officer; and Dan Chard, Vice President of Sales and Operations. Just a reminder, during the call, comments can and will be made that include forward-looking statements. These statements involve risks and uncertainties, and actual results may differ materially from those discussed or anticipated. We encourage you to refer to today’s earnings release and our SEC filings for a complete discussion of these risks. And with that, I'll turn the time over to Truman. I am sorry, Ritch.

I will go ahead. Good morning everyone and as always thank you again for joining us on the call today. By all measures 2013 was a great year and we are pleased with the growth that we enjoyed globally with everyone of our geographic regions contributing to our success. We also generated significant growth in our active accounts and in our sales force. Our success in 2013 was to rebuild the focused and consistent effort and execution from the global Nu Skin family. The fourth quarter was our first $1 billion quarter with solid results in all of our regions. Note that the fourth quarter included approximately $350 million in LPL sales. This all led to a record year with revenue exceeding $3 billion, annual revenue growth up 49% positively impacted the rest of the income statement with the operating margin for the year reaching 17.4%. Earnings per share for the quarter and the year were also strong and we generated cash from operations of $530 million, up from $311 million in 2012. We returned cash to shareholders by paying $71 million in dividends and repurchasing $141 million of common stock in 2013 leaving our stock repurchase authorization at year end at $395 million. I would also note that we recently reclassified a small portion of our selling expenses as a contract revenue rebate. This reclassification reduced revenue and selling expenses by about $19 million in the fourth quarter and $59 million for the year. This reclassification has no impact on operating income, net income, earnings per share or cash flow, but resulted in slightly lower revenue than the company's previous estimate. The presentation of financial data for previous period has been similarly reclassified for comparative purposes. Our balance sheet continues to be strong as we completed the year with…

Thank you Rich and good morning everyone. Today I’d like to provide some additional highlights of the year as well as provide some commentary on our outlook for 2014. First, in 2013, we added a significant new product to our ageLOC anti-aging line-up, the TR90 weight management and body shaping system. We launched this product system through a global limited time offer and generated approximately $560 million in sales, making it largest product launch in our company’s history. Since launching the ageLOC brand in 2008, we have generated over $3 billion in sales of ageLOC products, making it a key growth driver for our business. And thanks to our product development team, we enjoy a robust pipeline. We believe we’ll deliver a steady stream of innovation for many years to come. Last year we also made significant investments in advancing Nu Skin’s long-term growth prospects with the completion of the Nu Skin innovation center and campus expansion here at our corporate headquarters. And we’re also in the process of completing a new innovation product in Shanghai that will serve as our regional headquarters for the Greater China region. This facility also will include new product development labs and manufacturing facilities. We finished the year by celebrating our largest ever global convention, with sales leaders joining us from more than 50 countries. At this event we celebrated the achievements of our sales force and we also renewed our long-term vision of becoming world’s leading drug selling company. Now as we turn to 2014, we recognize that shareholders want to understand the direction of the business and what we forecast for the remainder of the year given the media and regulatory attention in China. Our primary objective today is to cooperate with the Chinese government in their review of our business. We…

Ladies and gentlemen that concludes today's conference. Thank you all for your participation. You may all now disconnect. Have a wonderful day.